VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GRDNGuardian Pharmacy Services, Inc.
$46.94$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGRDNP/E History

GRDN logoGuardian Pharmacy Services, Inc. (GRDN) P/E Ratio History

Fairly Valued

Trading at 40.1x, near 5Y avg of 40.2x · 40th percentile · In line with own history · Data 2025–2026

Current P/E (TTM)
40.1x
-0% vs 5Y avg
5Y Avg P/E
40.2x
Median 40.7x
5Y Percentile
40th
Mid-range
PEG Ratio
2.14
Premium to growth
5-Year P/E Range
40.1x
Min34.9xMedian40.7xMax45.4x
TTM EPS$1.17
Price$46.94
Earnings Yield2.49%
EPS Growth (1Y)144.1%
EPS Growth (5Y)18.8%

Loading P/E history...

P/E Ratio Analysis

As of November 21, 2026, Guardian Pharmacy Services, Inc. (GRDN) trades at a price-to-earnings ratio of 40.1x, with a stock price of $46.94 and trailing twelve-month earnings per share of $1.17.

The current P/E is roughly in line with its 5-year average of 40.2x. Over the past five years, GRDN's P/E has ranged from a low of 34.9x to a high of 45.4x, placing the current valuation at the 40th percentile of its historical range.

Compared to the Healthcare sector median P/E of 24.4x, GRDN trades at a 65% premium to its sector peers. The sector includes 249 companies with P/E ratios ranging from 0.0x to 185.4x.

The PEG ratio of 2.14 (P/E divided by 144% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, GRDN commands a significant premium over the S&P 500 median P/E of 20.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GRDN DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GRDN Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
40.1vs24.4
+65%
Above Sector
vs. S&P 500
40.1vs20.9
+92%
Above Market
PEG Analysis
2.14
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 144% EPS growth (1Y)

GRDN P/E vs Peers

Drug Distributors & Pharmacies peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
OMCL logoOMCLOmnicell, Inc.
$1B33.8--84%
CVS logoCVSCVS Health Corp.
$103B9.4Lowest--62%
MCK logoMCKMcKesson Corporation
$125B26.6-+49%Best
CAH logoCAHCardinal Health, Inc.
$64B35.01.24+12%
VEEV logoVEEVVeeva Systems Inc.
$43B43.32.38+26%
ENSG logoENSGThe Ensign Group, Inc.
$10B26.21.90+14%
ADUS logoADUSAddus HomeCare Corporation
$2B20.51.02Best+23%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

GRDN Historical P/E Data (2025–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q3Sep 30 2026$40.78$1.1734.9x-13%
FY2026 Q2-$41.87$1.0340.7x+1%
FY2026 Q1-$37.66$0.8345.4x+13%
FY2025 Q4Dec 31 2025$30.09$0.7739.1x-3%
FY2025 Q3-$26.23$0.6441.0x+2%

Average P/E for displayed period: 40.2x

Export Data
Consensus & Technical Research Suite
Open GRDN Terminal

GRDN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

1+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

GRDN — Frequently Asked Questions

Quick answers to the most common questions about buying GRDN stock.

What is GRDN's P/E ratio?

Guardian Pharmacy Services, Inc. (GRDN) trailing twelve-month P/E ratio is 40.1x, based on TTM diluted EPS of $1.17. The 5-year average P/E is 40.2x and the historical range spans 34.9x to 45.4x.

Is GRDN stock overvalued or undervalued?

GRDN trades at 40.1x P/E, near its 5-year average of 40.2x. The 40th percentile ranking within the 34.9x–45.4x historical range places valuation within normal bounds.

Is GRDN stock expensive?

GRDN is fairly valued relative to its own history. The current P/E of 40.1x is near the 5-year average of 40.2x (40th percentile of historical range).

What is GRDN's historical P/E range?

Over the past 5 years, GRDN's P/E ratio has ranged from 34.9x to 45.4x, with a median of 40.7x and an average of 40.2x. The current P/E of 40.1x places the stock at the 40th percentile of this range. Full historical data spans 2025–2026.

How does GRDN's P/E compare to the S&P 500?

GRDN trades at 40.1x P/E versus the S&P 500 median of 20.9x. The 92% premium to the market typically reflects higher expected earnings growth or quality.

How does GRDN's valuation compare to Healthcare peers?

Guardian Pharmacy Services, Inc. P/E of 40.1x compares to the Healthcare sector median of 24.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is GRDN's PEG ratio?

GRDN PEG ratio is 2.14, based on a P/E of 40.1x and EPS growth of 144.1%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.

What is GRDN's earnings yield?

GRDN earnings yield is 2.49%, the inverse of its 40.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

GRDN P/E Ratio History (2025–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current34.9x
Period Avg40.2x
Range34.9x - 45.4x
Change-15%
5 quartersSep 30, 2025 - Sep 30, 2026